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ABSTRACT
Smad2, Smad3 and Smad4 proteins are considered
to be key mediators of transforming growth factor-b
(TGF-b) signaling. However, the identities of the
Smad partners mediating TGF-b signaling are not
fully understood. Here, we show that RNA-binding
protein with multiple splicing (RBPMS), a member of
the RNA-binding protein family, physically interacts
with Smad2, Smad3 and Smad4 both in vitro and
in vivo. The presence of TGF-b increases the binding
of RBPMS with these Smad proteins. Consistent
with the binding results, overexpression of RBPMS
enhances Smad-dependent transcriptional activity
in a TGF-b-dependent manner, whereas knockdown
of RBPMS decreases this activity. RBPMS interacts
with TGF-b receptor type I (TbR-I), increases phos-
phorylation of C-terminal SSXS regions in Smad2
and Smad3, and promotes the nuclear accumulation
of the Smad proteins. Moreover, RBPMS fails to
enhance the transcriptional activity of Smad2 and
Smad3 that lack the C-terminal phosphorylation
sites. Our data provide the first evidence for an
RNA-binding protein playing a role in regulation of
Smad-mediated transcriptional activity and suggest
that RBPMS stimulates Smad-mediated transactiva-
tion possibly through enhanced phosphorylation of
Smad2 and Smad3 at the C-terminus and promotion
of the nuclear accumulation of the Smad proteins.
INTRODUCTION
Transforming growth factor-b (TGF-b) is a ubiquitously
expressed cytokine that regulates a variety of biological
processes, including cell growth, differentiation, matrix pro-
duction, apoptosis and development (1–3). TGF-b signaling
is initiated by ligand binding to the transmembrane receptor
serine–threonine kinases, TGF-b receptor type I (TbR-I) and
type II (TbR-II). Binding of TGF-b to TbR-II induces forma-
tion of heteromeric complexes of TbR-I and TbR-II. TbR-II
then activates TbR-I by phosphorylating the glycine–serine
domain of TbR-I. The activated TbR-I phosphorylates
receptor-regulated Smads (R-Smads), including Smad2 and
Smad3 in TGF-b signaling, thereby promoting their open con-
formation. In this state, these receptor-activated Smads can
form complexes with a common mediator Smad, Smad4, and
translocate to the nucleus, where they bind DNA and regulate
transcription of TGF-b responsive target genes.
Smad2, Smad3 and Smad4 are considered to be key
mediators of TGF-b signaling (4,5). These Smad proteins
contain highly conserved N- and C-terminal domains,
known as the Mad homology 1 (MH1) and Mad homology
2 (MH2) domains, respectively. Between these two domains
is the linker region rich in proline residues. The MH1 domain
is responsible for DNA binding, whereas the MH2 domain is
endowed with transcriptional activation properties. Smad2
and Smad3 can be phosphorylated both at the C-terminal
SSXS regions and at the linker region. In contrast to Smad2
and Smad3, Smad4, a protein of 552 amino acids, is not
regulated by phosphorylation, but acts as a central mediator
of TGF-b signaling. The Smad4 C-terminal domain (amino
acids 260–552), when fused to the GAL4 DNA-binding
domain, can stimulate transcription, suggesting that it may
contain transactivation activity (6). Alterations in Smad2
and Smad4 genes have been found to associate with many
types of human cancers, and thus Smads are considered to
be important tumor suppressors (7,8). Numerous transcription
factors and coregulators have been recently identiﬁed to
interact with Smads and regulate the signaling outcome
(9,10). They include the AP-1 family (11–13), steroid recep-
tor family (14), CBP/p300 (15), P/CAF (16), TGIF (17), Ski
(18,19), SnoN (20), SNIP1 (21) and many others. The Smad
transcriptional complexes can regulate transcription both
positively and negatively. Although many proteins have
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signaling pathways modulating TGF-b responsive gene
expression are not fully elucidated.
Using a lac operator/repressor tethering system (22), we
previously demonstrated that the Smad4 C-terminal region
(amino acids 260–514) can mediate large-scale chromatin
unfolding in mammalian cells, suggesting that the region
260–514 of Smad4 plays an important role in gene transcrip-
tion (23). To search for proteins responsible for Smad4-
mediated transcription, we have performed yeast two-hybrid
screens using amino acids 260–514 of Smad4 as bait, and
identiﬁed RNA-binding protein with multiple splicing
(RBPMS) as a novel Smad4-interacting protein. RBPMS is
a member of one of the largest families of RNA-binding
proteins, the RNA Recognition Motif (RRM) family (24).
RBPMS contains a single RRM domain at the N-terminus
and is human homologue of Xenopus hermes (25–28).
However, the function of RBPMS is unknown. Here, we
show that RBPMS physically interacts with Smad2, Smad3
and Smad4 in vitro and in vivo. Overexpression of RBPMS
enhanced Smad-mediated transcriptional activity, whereas
knockdown of endogenous RBPMS with small interfering
RNA (siRNA) signiﬁcantly inhibits the transcriptional
activity. RBPMS increases Smad-mediated transcriptional
activity possibly through increased phosphorylation of
Smad2 and Smad3 at the C-terminal SSXS regions and pro-
motion of the nuclear accumulation of the Smad proteins.
MATERIALS AND METHODS
Plasmids
The reporter constructs p3TP-Lux (29) and lac-Luc (22) have
been described previously. The TbR-I expression vector is a
gift from Dr Mark C. Wilkes (30). The entire coding
sequences of Smad2, Smad3 and Smad4 were isolated from
human embryonic kidney 293T cells by RT–PCR, and cloned
in frame into a pcDNA3 vector (Invitrogen) or the pcDNA3
linked with Escherichia coli lac repressor at the N-terminus.
Enhanced green ﬂuorescent protein (GFP)-tagged fusion
protein constructs were made by inserting PCR-ampliﬁed
Smad cDNA fragments into pEGFP-C1 (Clontech). The
mammalian expression vectors for RBPMS and its deletion
mutants were constructed by ampliﬁcation of each sequence
by standard PCR or recombinant PCR methods, and the
resulting fragments were inserted in frame into the
pcDNA3 linked with FLAG at the N-terminus. Prokaryotic
vectors encoding GST- and His-tagged fusion proteins were
prepared by PCR ampliﬁcation of each sequence, and the
resulting fragments were cloned in frame into pGEX-KG
(Amersham Pharmacia Biotech) and pET28a (Novagen),
respectively. For the yeast two-hybrid assay, the bait plasmid
pGBKT7-Smad4 (260–514) was generated by inserting a
PCR-ampliﬁed cDNA fragment containing most of the
MH2 domain of Smad4 into pGBKT7 (Clontech). All plas-
mids were veriﬁed by restriction enzyme analysis and DNA
sequencing. Details of cloning are available upon request.
Yeast two-hybrid assay
The bait plasmid pGBKT7-Smad4 (260–514) was used to
screen a human mammary gland cDNA library fused to
the GAL4 activation domain in pACT2 (Clontech) according
to the manufacturer’s instructions. Transformants were plated
on synthetic medium lacking tryptophan, leucine, adenine
and histidine but containing 1 mM 3-aminotriazole. Approxi-
mately 0.8 million transformants were screened. The screened
positive clones were also veriﬁed by one-on-one transforma-
tions and selection on agar plates lacking tryptophan and
leucine, or adenine, histidine, tryptophan and leucine, respec-
tively, and were also processed by b-galactosidase assay.
GST pull-down assay
The GST- and His-tagged fusion proteins were expressed and
puriﬁed by glutathione–Sepharose 4B beads (Amersham
Pharmacia) and Ni-NTA agarose (Qiagen), respectively.
The expression plasmid for RBPMS was used for in vitro
transcription and translation in the TNT system (Promega).
The
35S-labeled RBPMS or the puriﬁed His-tagged fusion
protein was incubated with GST fusion protein bound to
glutathione–Sepharose beads in 0.5 ml of the binding buffer
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
0.3 mM DTT, 0.1% NP-40) at 4 C. The beads were precipi-
tated, washed four times with the binding buffer, eluted by
boiling in SDS sample buffer, and analyzed by SDS–
PAGE. The gel was then dried and exposed to X-ray ﬁlm
overnight, or western blot was performed using anti-His
(Amersham Pharmacia).
Antibody production
The GST-RBPMS (130–220) fusion protein was expressed in
bacteria and puriﬁed using glutathione–Sepharose 4B beads
according to the manufacturer’s protocol (Amersham Phar-
macia). To generate polyclonal RBPMS antibody, the
puriﬁed GST-RBPMS (130–220) protein were injected sub-
cutaneously into each of two BALB/c female mice. Sera
from the immunized mice were collected and puriﬁed by
afﬁnity chromatography according to the manufacturer’s
instructions (Pierce).
Co-immunoprecipitation
For transfection-based co-immunoprecipitation assays, 293T
cells were transfected with the indicated plasmids using Lipo-
fectamine 2000 (Invitrogen), lysed in 0.5 ml lysis buffer
(50 mM Tris at pH 8.0, 150 mM NaCl, 0.25% NP-40,
1 mM DTT and protease inhibitor tablets from Roche), and
immunoprecipitated with anti-FLAG agarose beads (Sigma-
Aldrich) for 3 h at 4 C. The beads were washed four times
with the lysis buffer, and eluted in SDS sample buffer. The
eluted proteins were separated by SDS–PAGE, followed by
western blotting with anti-GFP (Clontech) or anti-FLAG
(Sigma-Aldrich) antibody.
For detecting interaction of endogenous Smad4 with
RBPMS, cells were lysed in 0.5 ml lysis buffer and immuno-
precipitated with anti-Smad4 or control serum (Santa Cruz).
After extensive washing with the lysis buffer, the immuno-
precipitates were resolved by SDS–PAGE, followed by
western blot analysis using the anti-RBPMS.
Reporter assay
293T cells were transfected with the p3TP-Lux or lac-
Luc reporter, b-galactosidase reporter, and the indicated
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according to the manufacturer’s instructions. After transfec-
tion, cells were treated with 5 ng/ml TGF-b1 for 20 h in
medium containing 0.5% FBS or in serum-free medium. To
test the role of autocrine TGF-b in TGF-b signaling, either
control IgG or TGF-b neutralizing antibody (R&D Systems)
was added to the culture. b-galactosidase reporter was used as
an internal control. Luciferase and b-galactosidase activities
were determined as described previously (31). All experi-
ments were repeated at least three times with similar results.
siRNA experiments
siRNA was designed using the web-based insert design tool
at www.ambion.com/techlib/misc/psilencer_converter.html.
The pSilencer2.1-U6neo vector (Ambion)-based siRNA was
made according to the manufacturer’s instructions. The cDNA
target sequences of siRNAs for RBPMS were AACATAC-
CAACCTACTGCAGA (RBPMS siRNA1) and AAACAC-
TACGACTAGAGTTTG (RBPMS siRNA2), respectively.
Plasmid pSilencer2.1-U6 neo Negative Control (Ambion)
was used as a control vector. Transient transfections of the
vector-based siRNAs into 293T cells were performed using
Lipofectamine 2000 (Invitrogen), and the cells were har-
vested at different hours after transfection.
Kinase assays
293T cells were transfected with expression vector for
FLAG-tagged RBPMS or empty vector in the absence or
presence of 5 ng/ml TGF-b1 in combination with 10 mM
TbR-I inhibitor SB-431542. The transfected cells were
lysed in 0.5 ml lysis buffer (50 mM Tris at pH 8.0,
150 mM NaCl, 0.25% NP-40, 1 mM DTT and protease
inhibitor tablets from Roche), and immunoprecipitated with
anti-FLAG agarose beads (Sigma-Aldrich). Immune com-
plexes were washed three times in kinase assay buffer
(50 mM HEPES at pH 7.5, 10 mM MgCl2, 1 mM DTT,
2.5 mM EGTA, 0.1 mM Na3VO3, 1 mM NaF). Pellets were
resuspended in 50 ml of kinase assay buffer supplemented
with 5 mCi of g-
32P-ATP and 5 mg of puriﬁed His-tagged
Smad2 or Smad3 or their mutants. Assays were performed
at 30 C for 30 min and then were stopped by addition of
SDS loading buffer. The reaction products were analyzed
by SDS–PAGE and autoradiography.
Subcellular fractionation
Cells were homogenized using a Dounce homogenizer in
1 ml of Buffer A (20 mM HEPES pH 7.9, 10 mM KCl,
1.5 mM MgCl2, 0.5 mM DTT, 0.1 mM EDTA, 0.1 mM
EGTA, with a cocktail of protease inhibitors from Roche). The
homogenate was centrifuged at 366 g for 10 min at 4 C. The
pellet was washed once with Buffer A, resuspended in SDS
loading buffer, and analyzed as the nuclear fraction. The super-
natant was centrifuged again at 13201 g for 10 min at 4 C, and
the ﬁnal supernatant analyzed as the cytoplasmic fraction. The
total protein concentrations of different fractions were deter-
mined by the BCA protein assay method (Pierce). An equal
amount of total proteins was analyzed by SDS–PAGE fol-
lowed by western blotting.
Poly(U) RNA pull-down assay
The poly(U) RNA pull-down assay was performed essentially
as described by Babic et al. (32). Brieﬂy, cell lysates were
incubated with poly(U) agarose beads (Amersham Pharmacia
Biotech), or agarose beads alone (Santa Cruz Biotech), for 1 h
at 4 C. The beads were washed with lysis buffer and resus-
pended in SDS–PAGE sample buffer. Proteins were separated
by SDS–PAGE, followed by immunoblotting with the indi-
cated antibody.
RESULTS
Identification of RBPMS as a Smad4-interacting
protein by yeast two-hybrid system
To identify novel Smad4-interacting proteins, we performed a
yeast two-hybrid screening of a human mammary cDNA
library using amino acids 260–514 containing most of the
Smad4 MH2 domain as bait. Screening of  0.8 million trans-
formants resulted in the isolation of several positive clones.
Sequencing of the positive clones identiﬁed several clones
that encoded the full-length cDNA of RBPMS gene. To fur-
ther conﬁrm the interaction of RBPMS with Smad4 in yeast,
we transformed RBPMS in pACT2 vector harboring GAL4
activation domain or pACT2 vector, together with
Smad4(260–514) in pGBKT7 vector harboring GAL4
DNA-binding domain (DBD) or together with an unrelated
protein, lamin C, fused to the GAL4 DBD. The transformed
colonies with RBPMS and Smad4(260–514) showed both the
ability to grow in medium lacking adenosine, histidine, tryp-
tophan and leucine, and to turn blue in a b-galactosidase
assay, whereas cotransfections with the control vectors did
not do so (Figure 1A). These data demonstrated that
RBPMS interacts with Smad4 in yeast cells.
Interaction of RBPMS with Smad4 in vivo and in vitro
To conﬁrm the interaction between RBPMS and Smad4, we
next examined the ability of RBPMS protein to bind to
Smad4 in mammalian cells. 293T cells were co-transfected
with FLAG-tagged RBPMS, E.coli lac repressor (lac)-tagged
Smad4, or lac control vector. Immunoprecipitation (IP) of
cell lysates with an anti-FLAG monoclonal antibody was
followed by immunoblotting (IB) with anti-lac. Results
showed a speciﬁc interaction between the FLAG-RBPMS
and lac-Smad4 (Figure 1B). To demonstrate the interaction
of RBPMS and Smad4 in vitro, GST pull-down assays
were performed in which in vitro translated
35S-methionine-
labeled RBPMS was incubated with full-length GST-
Smad4 or GST. As shown in Figure 1C, RBPMS interacted
with GST-Smad4 but not with GST alone. These results indi-
cate that RBPMS interacted with Smad4 in vivo and in vitro.
As an initial step to examine if RBPMS physiologically
interacts with Smad4, mouse RBPMS polyclonal antibody,
which is not commercially available, was developed. To
determine the speciﬁcity of the anti-RBPMS antibody,
293T cells were transfected with expression vector for
FLAG-tagged RBPMS or its empty vector control. Immuno-
blotting of whole cell extracts with anti-FLAG demonstra-
ted a single band with a molecular weight of  25 kDa
in 293T cells transfected with the FLAG-tagged RBPMS
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(Figure 1D, left panel), whereas immunoblotting with anti-
RBPMS showed a single band both in 293T cells transfected
with the FLAG-tagged RBPMS construct and in 293T cells
transfected with the control vector (Figure 1D, right panel).
However, the intensity of the band in 293T cells transfected
with the FLAG-tagged RBPMS construct was much stronger
than that in 293T cells transfected with the control vector,
indicating that 293T cells expressed endogenous RBPMS.
Due to the small size of the FLAG tag, FLAG-tagged
RBPMS could not be clearly distinguished from endogen-
ous RBPMS. Detection of FLAG-tagged RBPMS was
completely blocked by pre-incubating anti-RBPMS with
the cognate GST-RBPMS fusion protein but not by pre-
incubating with GST (data not shown). These data indicate
that anti-RBPMS speciﬁcally recognizes RBPMS.
To ascertain the interaction of RBPMS with Smad4 in
a more physiological context, the endogenous Smad4 protein
from 293T cells was immunoprecipitated with an anti-Smad4
antibody. Subsequent immunoblotting with anti-RBPMS
antibody indicated that the endogenous RBPMS was copre-
cipitated with Smad4 (Figure 1E) in both the absence and
presence of TGF-b1. However, addition of TGF-b1 enhanced
the interaction of Smad4 with RBPMS. In the negative
control experiment, normal mouse serum or an irrelevant
antibody, anti-FLAG monoclonal antibody, did not immuno-
precipitate RBPMS (Figure 1E and data not shown). Taken
together, these data strongly suggest that RBPMS interacts
with Smad4 under physiological condition.
Mapping of the Smad4 and RBPMS interaction regions
To deﬁne the region of RBPMS required for its interaction
with Smad4, GST pull-down experiments were performed
in which two deletion mutants, GST-RBPMS(1–100) contain-
ing the RRM and GST-RBPMS(101–219), were incubated
with puriﬁed His-tagged Smad4. As shown in Figure 2A,
the GST-RBPMS(1–100) bound speciﬁcally to Smad4,
but the GST-RBPMS(101–219) and GST did not, suggesting
that the RRM region is required for the interaction with
Smad4.
To deﬁne the binding region or regions of Smad4 that are
important for RBPMS interaction, Smad4 encompassing
different regions, including the N-terminal MH1 domain
Figure 1. RBPMS interacts with Smad4 in yeast, in mammalian cells and in vitro.( A) Identification of RBPMS as a Smad4-interacting protein by the yeast two-
hybrid assay. Yeast AH109 cells were transformed with different plasmids and grown on SD/ Trp Leu His Ade. +, grown within 96 h;  , no growth within
96 h. Positive colonies were tested for b-galactosidase activity. +, turned blue within 2 h;  , did not turn blue within 2 h. (B) Interaction of RBPMS with Smad4
in mammalian cells. 293T cells, cultured in regular medium, were transfected with expression plasmids as indicated. Immunoprecipitation (IP) was performed
using anti-FLAG monoclonal antibody (Sigma-Aldrich), and immunoblotted (IB) with anti-lac polyclonal antibody (Stratagene). (C) Interaction of RBPMS with
Smad4 in vitro. Glutathione–Sepharose beads bound with GST-Smad4 or with GST were incubated with
35S-labeled RBPMS. After washing the beads, the bound
proteins were eluted and subjected to SDS–PAGE and autoradiography. (D) Characterization of anti-RBPMS mouse antiserum by immunoblotting. The lysates
from 293T cells transfected with FLAG-RBPMS or its empty vector were prepared and the proteins detected with anti-FLAG (left panel) or anti-RBPMS (right
panel) antibody. (E) Interaction of endogenous RBPMS with Smad4 in vivo. 293T cells, cultured in serum-free medium, were treated without and with 5 ng/ml
TGF-b1 for 1 h. Cell lysates were immunoprecipitated with either anti-Smad4 antibody or preimmune control serum (Santa Cruz). The precipitates were
analyzed by immunoblot using anti-RBPMS.
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(136–322)], the C-terminal MH2 domain [GST-Smad4(322–
552)], and the partial linker region [GST-Smad4(250–322)],
was generated (Figure 2B). The results of the GST pull-
down assays indicated that both MH1 and MH2 domains
interacted with RBPMS, with the MH1 displaying higher
binding afﬁnity, whereas the linker regions, including GST-
Smad4(136–322) and GST-Smad4(250–322), had negligible
binding ability.
Interaction of RBPMS with Smad2 and Smad3 in vivo
and in vitro
Since RBPMS was shown to interact with both the MH1
and the MH2 domains of Smad4, which are two highly
conserved domains among Smad2, Smad3 and Smad4, the
speciﬁcity of the interaction between RBPMS and Smad4
was determined by co-immunoprecipitaion experiments.
FLAG-tagged RBPMS and GFP-tagged Smad2, Smad3 or
Smad4 were cotransfected into 293T cells. Cells were then
subjected to immunoprecipitation with FLAG antibody-
conjugated agarose beads followed by immunoblot with
GFP antibody. As shown in Figure 3A–C, all of the Smad
proteins could be co-immunoprecipitated in the presence,
but not in the absence, of FLAG-RBPMS, with or without
exogenous TGF-b1. In all cases, however, TGF-b1 increased
the interaction of RBPMS with Smad2, Smad3 and Smad4
in vivo. Furthermore, RBPMS did not associate with
Smad2 and Smad3 phosphorylated on their C-terminal
SSXS motif (Figure 3A and B), as measured by immunoblot-
ting with anti-phospho-Smad2/3(Ser423/425), which recog-
nizes Smad3 phosphorylated at Ser-423 and Ser-425
and corresponding phosphorylated Smad2 (Ser-465 and
Ser-467).
To examine whether the interaction of RBPMS with
the Smad proteins is mediated by RNA, the ability of
RBPMS to bind to RNA was ﬁrst determined by poly(U)
RNA pull-down experiments. Consistent with previous report
demonstrating that hermes, the Xenopus homolog of RBPMS,
can associate with poly(A) RNA in vivo, RBPMS can also
efﬁciently bind to RNA (Figure 3D). However, the in vivo
interaction of RBPMS with Smad2, Smad3 and Smad4 was
unlikely to be mediated by RNA, as it was not affected by
RNase treatment prior to immunoprecipitation (Figure 3E,
upper panel), although RNase could efﬁciently digest RNA
(Figure 3E, lower panel).
To test if RBPMS can interact directly with Smad2, Smad3
and Smad4, puriﬁed GST-RBPMS was mixed with puriﬁed
His-tagged Smad2, Smad3 and Smad4 in binding assays.
Consistent with the in vivo results, all of the Smad proteins
directly interacted with RBPMS (Figure 3F). Taken together,
these data suggest that conserved amino acids of the Smad
proteins may be responsible for the interaction of RBPMS
with Smad2, Smad3 and Smad4.
Overexpression of RBPMS enhances
TGF-b/Smad-mediated transactivation
To determine the effects of RBPMS on TGF-b/Smad-
mediated transcription, 293T cells were cotransfected with
the synthetic TGF-b-responsive transcriptional reporter
p3TP-Lux and increasing amounts of RBPMS. As shown in
Figure 4A, in both the absence and presence of exogenous
TGF-b, RBPMS stimulated the reporter gene transcription
in a dose-dependent manner. Consistent with the binding
results, the magnitude of the reporter activation in the pres-
ence of TGF-b1 was greater than that in the absence of
TGF-b1. RBPMS did not increase the protein levels of
Smad2, Smad3 and Smad4 (Figure 4B), suggesting that this
enhanced transcriptional activity was not a result of increased
Smad protein production.
The observations that RBPMS enhanced the p3TP-Lux
reporter activity in the absence of exogenous TGF-b raise
the possibility that overexpression of RBPMS might confer
ligand-independent activation of the reporter or RBPMS-
induced increase in the reporter activity in the absence of
Figure 2. Mapping of the RBPMS and Smad4 interaction regions. (A)
Mapping of Smad4 interaction region in RBPMS. Purified His-Smad4 was
incubated with full-length GST-RBPMS, GST-RBPMS(1–100) or GST-
RBPMS(101–219), or with GST. The bound proteins were subjected to SDS–
PAGE followed by immunoblotting with anti-His antibody (Amersham
Pharmacia). Also presented is a schematic diagram of the RBPMS protein,
illustrating the location of the RNA recognition motif (RRM). SDS–PAGE
analysis of the purified GST-fusion proteins is shown at the bottom. (B)
Mapping of RBPMS interaction region in Smad4. Purified His-RBPMS was
incubated with full-length GST-Smad4, GST-Smad4(1–136), GST-
Smad4(136–322), GST-Smad4(322–552) or GST-Smad4(250–322), or with
GST. Bound proteins were detected by immunoblotting using anti-His
antibody. SDS–PAGE analysis of the purified GST-fusion proteins is shown
at the bottom.
6318 Nucleic Acids Research, 2006, Vol. 34, No. 21exogenous TGF-b could be due to an autocrine TGF-b
response. To test this possibility, transfected cells were trea-
ted with a TGF-b neutralizing antibody. The antibody treat-
ment of 293T cells completely abolished the reporter
activation by RBPMS (Figure 4C). These results suggest
that TGF-b is required for RBPMS-induced increase in the
reporter activity and the RBPMS activity in the absence of
exogenous TGF-b is due to autocrine TGF-b.
To investigate whether Smad4, a central mediator in
TGF-b signaling, is required for the effect of RBPMS on
the 3TP-Lux reporter gene transcription, human breast cancer
MDA-MB-468 cells, which lack endogenous Smad4 (33),
were cotransfected with the 3TP-Lux reporter and RBPMS,
together with or without Smad4. Cotransfection of RBPMS
and the 3TP-Lux reporter in MDA-MB-468 cells did not
increase the p3TP-Lux reporter transcription, whereas
Figure 3. RBPMS interacts with Smads in vivo and in vitro.( A–C) Interaction of RBPMS with Smads in vivo. FLAG-tagged RBPMS and GFP-tagged Smad2,
Smad3 or Smad4 were cotransfected into 293T cells in the presence or absence of 5 ng/ml TGF-b1. Cell lysates were immunoprecipitated (IP) by anti-FLAG
monoclonal antibody (Sigma-Aldrich), and the precipitates were then immunoblotted (IB) with anti-GFP antibody (Clontech) or anti-phospho-Smad2/3(Ser423/
425) antibody (Santa Cruz). (D) Association of RBPMS with poly(A) RNA in vivo. 293T cells were transfected with FLAG-tagged RBPMS or empty vector in
the presence or absence of 5 ng/ml TGF-b1. Cell lysates were used for poly(U) RNA agarose or agarose alone pull-down assays. After pull-downs, the RBPMS
protein was detected with anti-FLAG antibody. The RBPMS in the cell lysates prior to pull-downs is used as an input. (E) Effect of RNA on the interaction of
RBPMS with Smads in vivo. 293T cells were transfected in the presence of 5 ng/ml TGF-b1 and analyzed as in (A–C) except that cell lysates were treated with
100 mg/ml RNase before immunoprecipitation (upper panel). The isolated plasmid without RNase treatment was used as a control for RNase efficiency (lower
panel). (F) Direct interaction of RBPMS with Smads. E.coli-expressed His-Smad2, His-Smad3 and His-Smad4 were purified, and incubated with purified GST or
GST-RBPMS immobilized on glutathione–Sepharose beads. Bound proteins were analyzed by immunoblotting using anti-His antibody (upper panel). SDS–
PAGE analysis of the purified His-fusion proteins is shown at the bottom.
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vector led to activation of the p3TP-Lux (Figure 4D). There-
fore, RBPMS acts through Smad4 to increase p3TP-Lux
reporter transcription.
Since RBPMS can directly interact with Smad2, Smad3
and Smad4, the possibility that RBPMS may directly regulate
Smad transcriptional activity was tested. A lac repressor–lac
operator recognition system was used (22), in which Smad2,
Smad3 and Smad4 were fused to the lac repressor. As
previously reported (16), Smad2 and Smad3 had intrinsic
transcriptional activity, whereas Smad4 did not (Figure 4E).
Expression of RBPMS enhanced the transcriptional activity
of Smad2, Smad3 and Smad4, demonstrating the coactivator
function of RBPMS for these Smad proteins.
Figure 4. Overexpression of RBPMS increases TGF-b/Smad-mediated transactivation. (A) 293T cells were co-transfected with 0.2 mg of reporter p3TP-Lux and
increasing amounts of plasmid expressing FLAG-tagged RBPMS. Cells were treated with or without 5 ng/ml TGF-b1 and analyzed for luciferase activity.
(B) Western blotting showing the Smad2, Smad3, Smad4 and RBPMS protein levels. 293T cells were transfected as in panel A. Cell lysates were prepared from
293T cells transfected with 1 mg of the RBPMS expression vector, and were probed with anti-Smad2/3, anti-Smad4, anti-FLAG, or anti-GAPDH. (C) 293T cells
were co-transfected with 0.2 mg of p3TP-Lux and 1.0 mg of the expression vector of RBPMS in the absence or presence of 5 ng/ml TGF-b1 with or without 10 mg/
ml TGF-b neutralizing antibody (a-TGF-b). The cells were analyzed as in (A). (D) Smad4-negative MDA-MB-468 cells were co-transfected with 0.2 mgo f
p3TP-Lux, and 1.0 mg of the expression vector of RBPMS in both the absence and presence of the expression plasmid for Smad4. (E) 293T cells were co-
transfected with 0.2 mg of lac-Luc, 50 ng of the expression plasmid for lac-tagged Smad2, Smad3 or Smad4, and 1 mg of the expression vector for FLAG-tagged
RBPMS.
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TGF-b/Smad-mediated transactivation
To investigate the role of endogenous RBPMS in activation
of the p3TP-Lux reporter, 293T cells were transfected with
vector-based RBPMS siRNAs or universal scramble siRNA
(control). As shown in Figure 5A, RBPMS siRNA2 effec-
tively inhibited the expression of RBPMS protein, whereas
RBPMS siRNA1 and universal scramble siRNA had little
or no effect. As another control, the RBPMS siRNAs
did not reduce the expression of Smad2, Smad3 and Smad4
proteins (data not shown). Suppression of the normal expres-
sion of RBPMS in 293T cells by the speciﬁc RBPMS siRNA2
signiﬁcantly decreased the reporter activity (Figure 5B).
Consistent with the results of the overexpression experiments,
the magnitude of the reporter repression in the absence of
TGF-b1 was greater than that in the presence of TGF-b1.
Taken together, these results suggest that RBPMS can
enhance TGF-b responsive reporter activity both in a ligand-
indpendent and in a ligand-dependent manner.
Both the N-terminus and the C-terminus are required
for full function of RBPMS
To map the regions required for RBPMS transactivation
function, we generated two RBPMS deletion mutants in
which the N-terminal partial RRM and the C-terminus with-
out RRM were selectively deleted. RBPMS were compared
with the two RBPMS deletion mutants, FLAG-tagged
RBPMS(1–100) and FLAG-tagged RBPMS(D51–99), in
a transient transfection assay. As shown in Figure 6A,
while RBPMS stimulated TGF-b/Smad-regulated transcrip-
tion, RBPMS(1–100) that contains the interacting region of
RBPMS on Smad4 repressed the RBPMS activity in a
dose-dependent manner, indicating that RBPMS(1–100) has
a dominant-negative effect and that the C-terminus is required
for RBPMS activation possibly through recruitment of factors
important for transcriptional regulation. Deletion of the
N-terminal partial RRM (FLAG-tagged RBPMS(D51–99))
almost fully abolished the activity of RBPMS, suggesting
that the RRM is important for RBPMS transactivation in
addition to the C-terminus. Notably, FLAG-tagged RBPMS,
RBPMS(1–100) and RBPMS(D51–99) were expressed at
comparable levels (Figure 6B). Although we also tried to
delete the entire RRM, this mutant [RBPMS(101–220)] was
not expressed (data not shown). Taken together, the above
data suggest that both the RRM and the C-terminus are
required for full function of RBPMS.
RBPMS increases phosphorylation of C-terminal SSXS
regions in Smad2 and Smad3
Phosphorylation of Smad2 and Smad3 on their C-
terminal SSXS motif has been shown to be required for
Figure 5. Knockdown of endogenous RBPMS reduces TGF-b/Smad-
mediated transcriptional activity. (A) Western blotting with indicated
antibodies showing the specific knockdown effect of the two RBPMS
siRNAs on the endogeous RBPMS protein level. 293T cells were transfected
with expression vectors for two different RBPMS siRNAs or scramble siRNA
(control) plasmid. Forty-eight hours after transfection, whole-cell extracts
were prepared and probed with anti-RBPMS or GAPDH. (B) Luciferase
reporter assay in the control and RBPMS knockdown cells using the p3TP-
Lux reporter. 293T cells were co-transfected with 0.2 mg of p3TP-Lux, and
1.0 mg of RBPMS siRNA as indicated.
Figure 6. Full-length RBPMS is required for stimulation of TGF-b/Smad-
mediated transactivation. (A) Luciferase reporter assay with the RBPMS
deletion mutants. 293T cells were co-transfected with 0.2 mg of p3TP-Lux
and increasing amounts of the expression plasmid for FLAG-tagged RBPMS,
RBPMS(1–100) or RBPMS(D51–99) as indicated. (B) Western blotting
showing expression levels of FLAG-tagged RBPMS, RBPMS(1–100) or
RBPMS(D51–99) with antibody against FLAG or GAPDH. 293T cells were
transfected in the presence of TGF-b as in (A).
Nucleic Acids Research, 2006, Vol. 34, No. 21 6321TGF-b/Smad-mediated transcriptional activation (34–36). To
elucidate the mechanism for the enhanced transcriptional
activity of the Smad proteins by RBPMS, the effect
of RBPMS on the phosphorylation of Smad2 and Smad3
at the C-terminal regions was examined. 293T cells were
transfected with expression vector for FLAG-tagged
RBPMS or its empty vector. As shown in Figure 7A, the lev-
els of Smad2 and Smad3 phosphorylation on the C-terminal
Figure 7. C-terminal phosphorylation of Smad2 and Smad3 correlates with RBP coactivation of Smad2 and Smad3. (A) RBPMS increased phosphorylation of
Smad2 and Smad3 at the C-terminus. Serum-starved 293T cells were transfected with increasing amounts of the RBPMS expression vector or its empty vector as
indicated. Cells were treated with or without 5 ng/ml TGF-b1 for 1 h. Cell lysates were prepared and probed with anti-phospho-Smad2/3 (Ser 423/425) (Santa
Cruz Biotech), anti-Smad2/3 (Upstate), or anti-FLAG. (B) In vitro phosphorylation of Smad2 and Smad3 at the C-terminus by RBPMS immunoprecipitate. 293T
cells were transfected with 3 mg of the RBPMS expression vector or its empty vector, and treated with 5 ng/ml TGF-b1, in combination with 10 mMT bR-I
inhibitor SB-431542. Cell extracts were immunoprecipitated with anti-FLAG. In vitro kinase assays were performed using His-Smad2, His-Smad3 and their
C-terminal mutants (His-Smad2m and His-Smad3m) as substrates. The phosphorylated states of Smad2 and Smad3 were analyzed by SDS–PAGE and
autoradiography or immunoblotting with anti-phospho-Smad2/3 as indicated. The bottom panel indicates SDS–PAGE analysis of His-Smad2, His-Smad3 and
their mutant proteins purified from bacteria. (C) Interaction of RBPMS with TbR-I in vivo. FLAG-tagged TbR-I and HA-tagged RBPMS were cotransfected into
293T cells in the presence or absence of 5 ng/ml TGF-b1. Cell lysates were immunoprecipitated (IP) by anti-FLAG, and the precipitates were then
immunoblotted (IB) with anti-HA antibody. (D) RBPMS failed to increase the transcriptional activity of Smad2 and Smad3 that lack the C-terminal
phosphorylation sites. 293T cells were co-transfected with 0.2 mg of lac-Luc, 50 ng of the expression plasmid for lac-tagged Smad2, Smad3 or their C-terminal
mutants (lac-Smad2m and lac-Smad3m), and 1 mg of the expression vector for FLAG-tagged RBPMS, with or without 5 ng/ml TGF-b1. (E) Western blotting
with indicated antibodies showing expression levels of lac-tagged Smad2, Smad3 or their C-terminal mutants. 293T cells were transfected in the presence of 5 ng/
ml TGF-b1a si n( D).
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RBPMS, as measured by immunoblotting with anti-phospho-
Smad2/3. RBPMS increased the phosphorylation of Smad2
and Smad3 in a dose-dependent manner.
To further conﬁrm the phosphorylation stimulated by
RBPMS, in vitro kinase assay was performed. Immunopre-
cipitate of the cell extract from 293T cells transfected with
FLAG-tagged RBPMS or empty vector using anti-FLAG
was mixed with His-Smad2 or His-Smad3 puriﬁed from
bacteria. As another control, mutants of His-Smad2 and
His-Smad3 were used in which the C-terminal Ser 423 and
425 in Smad3 and Ser 465 and Ser 467 in Smad2 were chan-
ged to alanine. As shown in Figure 7B, both in the absence and
in the presence of exogenous TGF-b, RBPMS immunoprecipi-
tate could phosphorylate His-Smad2 and His-Smad3, but not
the mutants, as evidenced by SDS–PAGE and autoradiography
or immunoblotting with the anti-phospho-Smad2/3. The
RBPMS-induced phosphorylation of His-Smad2 and His-
Smad3 without exogenous TGF-b1 may be due to an autocrine
TGF-b response in 293T cells because treatment with the
TbR-I inhibitor SB-431542 completely abolished the in vitro
phosphorylation activity of the RBPMS immunoprecipitate.
The observations that the phosphorylation activity of
the RBPMS immunoprecipitate depends on TbR-I raise
the possibility that RBPMS may physically interact with
TbR-I. To test this possibility, FLAG-tagged TbR-I and
HA-tagged RBPMS were cotransfected into 293T cells, and
co-immunoprecipitation was performed. As shown in
Figure 7C, RBPMS speciﬁcally interacted with TbR-I, and
TGF-b enhanced the interaction of RBPMS with TbR-I. As
a positive control, Smad3 associated with TbR-I. These
data suggest that RBPMS immunoprecipitate speciﬁcally
phosphorylates the C-terminal SSXS regions of Smad2 and
Smad3 possibly through recruitment of TbR-I.
To establish a link between the C-terminal phosphorylation
and RBPMS coactivation of Smad2 and Smad3, 293T cells
were cotransfected with the lac-Luc reporter and RBPMS,
together with lac-tagged Smad2 and Smad3, or their mutants
in which the C-terminal Ser 423 and 425 in Smad3 and Ser
465 and Ser 467 in Smad2 were changed to alanine. As
expected, RBPMS increased Smad2- and Smad3-mediated
transcriptional activity (Figure 7D). The lac-Smad2 and
lac-Smad3 mutants lost their intrinsic transcriptional activity.
Importantly, RBPMS failed to enhance the transcriptional
activity of Smad2 and Smad3 that lack the C-terminal phos-
phorylation sites. It should be noted that lac-tagged Smad2
and Smad3 and their mutants were expressed at comparable
levels (Figure 7E). Thus, the C-terminal phosphorylation
of Smad2 and Smad3 strongly correlates with RBPMS
coactivation function.
RBPMS promotes the nuclear accumulation
of Smad proteins
Since RBPMS is a protein with unknown function, the
localization of RBPMS protein was determined by subcellular
fractionation, followed by immunoblotting with the anti-
RBPMS. 293T cells were fractionated into cytoplasmic and
nuclear fractions. As shown in Figure 8A, although RBPMS
was predominantly cytoplasmic, a signiﬁcant proportion
of RBPMS was detected in the nuclear fraction of 293T cells.
TGF-b1 did not appear to affect the subcellular localization of
the RBPMS protein.
As RBPMS can increase the phosphorylation of Smad2 and
Smad3 on their C-terminal SSXS motif, which has been
shown to be critical for translocation of these Smad proteins
from the cytoplasm to the nucleus (37), we hypothesized that
RBPMS could promote the nuclear accumulation of the Smad
proteins. To test this possibility, we transfected FLAG-tagged
RBPMS or its empty vector into 293T cells. In the absence
of exogenous TGF-b1, Smad2, Smad3 and Smad4 were
predominantly localized in the cytoplasm of the 293T cells,
whereas treatment with TGF-b1 increased the proportion of
these Smad proteins in the nuclear fraction (Figure 8B).
Intriguingly, the expression of RBPMS increased the propor-
tion of the Smad proteins in the nuclear fraction. These data
suggest that RBPMS promotes the nuclear accumulation of
Smad2, Smad3 and Smad4.
Ubiquitous expression of RBPMS protein
Although RBPMS has been shown to be expressed at
mRNA level, the expression of RBPMS protein remains to
Figure 8. RBPMS promotes the nuclear accumulation of Smad proteins.
(A) Subcellular localization of RBPMS. Serum-starved 293T cells were
treated with or without 5 ng/ml TGF-b1. The cells were then fractionated
into cytoplasmic and nuclear fractions. The lysates were probed with the
anti-RBPMS. Lamin A/C and a-tubulin were used as the nuclear and
cytoplasmic marker, respectively. (B) RBPMS-induced nuclear accumulation
of Smad proteins. Serum-starved 293T cells were transfected with 3 mg of the
FLAG-tagged RBPMS expression vector or its empty vector, and treated with
5 ng/ml TGF-b1. The cells were fractionated as in (A). The lysates were
detected with anti-FLAG, anti-Smad2/3 or anti-Smad4.
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performed in various human cell lines as well as in rat tissues
with the anti-RBPMS antibody. As shown in Figure 9A, a
speciﬁc band of RBPMS protein was detected in all of the
human cell lines tested, including breast cancer (MDA
-MB-231, MDA-MB-435 and MDA-MB-453), ovary cancer
(SKOV3), liver cancer (HepG2) and kidney cells (G401
and 293T), although with different levels. The speciﬁc band
was also present in all the rat tissues tested including heart,
liver, kidney, prostate, spleen, ovary, colon, skeletal muscle
and brain (Figure 9B). The wide distribution of RBPMS
suggests a potential function of RBPMS in modulation of
the general transcriptional machinery.
DISCUSSION
In this study, we showed that, like hermes, the Xenopus
homolog of RBPMS, RBPMS can interact with RNA
in vivo. To our knowledge, this is the ﬁrst evidence for an
RNA-binding protein playing a role in the regulation of Smad-
mediated transcriptional activity. Recently, many cofactors,
including coactivators and corepressors, have been identiﬁed
to interact with Smad proteins and modulate TGF-b/Smad-
mediated transcriptional activation. Most of the identiﬁed
cofactors are corepressors, such as Ski (18,19), SnoN (20)
and SNIP1 (21). Only a few coactivators, such as CBP/
p300 (15) and P/CAF (16), have been shown to interact
with Smad proteins and enhance TGF-b/Smad-induced tran-
scription. In the present study, we provide evidence of physi-
cal and functional interaction between the member of the
RNA-binding protein family RBPMS and Smad proteins.
The physical interaction has been validated by a number of
in vitro and in vivo experiments, including yeast two-hybrid,
in vitro GST pull-down, and in vivo co-immunoprecipitation.
Moreover, RBPMS directly interacts with Smad2, Smad3 and
Smad4. Importantly, we further show that RBPMS function-
ally enhances Smad-mediated transcriptional activity. Since
RBPMS is ubiquitously expressed in different cells in culture
as well as in various tissues, our data suggest that RBPMS
may be a novel coactivatior of Smad proteins and may play
roles in multiple tissues.
Although the function of human RBPMS remains
unknown, hermes, the Xenopus homolog of RBPMS, has
been shown to inhibit heart development in the developing
Xenopus embryo (25,26). Hermes is involved in the regula-
tion of mature transcripts required for myocardial differentia-
tion. Like other RNA-binding proteins, hermes can form a
multiprotein complex and bind to mature RNA transcripts.
Although RNA-binding proteins are generally considered to
participate in posttranscriptional regulation of gene expres-
sion (38,39), our study has identiﬁed a new role of RBPMS
in gene transcription. The fact that the RNA-binding domain
of RBPMS is required for RBPMS coactivation of Smad
transcriptional activity but RNA is not required for the
interaction of RBPMS with Smad proteins suggests that
RBPMS are involved in two separate events, transcriptional
and posttranscriptional regulation of gene expression, and
the binding of RBPMS to RNA and Smad proteins might
be mutually exclusive. However, we cannot exclude the
possibility that RBPMS may also modulate Smad-mediated
transactivation function through posttranscriptional regula-
tion. This hypothesis is supported by a recent ﬁnding that
regulators that interact with steroid hormone receptors,
which act as ligand-dependent transcription factors, served
as both coactivators and splicing factors (40). Taken together,
our data suggest that the RRM of RBPMS may function not
only as an RNA-binding domain that necessitates RNA-
binding but also as a protein–protein interaction domain
that may function independently of a RNA cofactor.
Recently, only a few RNA-binding proteins have been found
to play a role in gene transcription (41–43). For example, thyr-
oid hormone receptors (TRs), which belong to the nuclear
receptor superfamily, regulate target gene transcription by
interacting with DNA response elements and coregulatory pro-
teins. However, TRs also are single-stranded RNA binding
proteins, and the RNA-binding domain of TRs is important
for coactivation by SRA, an RNA coactivator for TRs as
well as steroid receptors (41). PRIP-interacting protein with
methyltransferase domain (PIMT) can bind to RNA but not
single- and double-stranded DNA. PIMT increases the tran-
scriptional activity of peroxisome proliferator-activated recep-
tor g (PPARg) and retinoid-X-receptor a (RXRa), which is
further stimulated by overexpression of PRIP, a coactivator
for PPARg (42). Although whether coactivator activator
(CoAA) binds RNA remains to be investigated, CoAA
contains two highly conserved RRMs commonly found in
ribonucleoproteins. CoAA potently enhances nuclear receptor-
mediated transcription and acts synergistically with TRBP
(TR-binding protein), which interacts with CoAA. Both the
two RRMs and the TRBP-interacting domain are required
for full function of CoAA (43). Our observation that the
RRM alone was inactive or inhibitory in RBPMS coactivation
of Smad proteins and that deletion of the partial RRM almost
completely abolishes the RBPMS activity suggests that
RBPMS acts similar to CoAA. Combined with the others,
Figure 9. Expression of RBPMS in different human cell lines as well as rat
tissues. RBPMS expression was detected by western blot with anti-RBPMS
using proteins from indicated human cell lines (A) as well as rat tissues (B).
GAPDH was used as a loading control.
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transcriptional regulation.
TGF-b was shown to exert transcriptional responses through
Smad2 and Smad3, which are direct TGF-b receptor sub-
strates. Receptor-mediated phosphorylation of these Smads
on the C-terminal SSXS motif induces their association with
the common partner Smad4, followed by translocation into
the nucleus, where these complexes regulate transcription of
target genes. Although receptor phosphorylation of Smad2
and Smad3 on the C-terminal SSXS motif is critical for
activation of TGF-b signaling, a possible regulatory role for
several other phosphorylation sites, especially in the linker
region, has been described (44–49). The phosphorylation
could be mediated by members of the mitogen-activated pro-
tein kinase (MAPK) family, which includes the extracellular
signal-regulated protein kinase (ERK) pathway (44) and two
stress-activated protein kinase (SAPK) pathways: the c-Jun
N-terminal kinase (JNK) and the p38 pathway (45–49), and
of the cyclin-dependent kinase (CDK) family, which include
CDK2 and CDK4 (49). Oncogenically activated Ras can
phosphorylate R-Smads, including Smad2 and Smad3, at
Ser/Thr-Pro (S/TP) sites in the linker region through ERK
kinases, and suppress Smad-dependent transcription. JNK
and/or p38 MAPK activated on TGF-b treatment can directly
phosphorylate R-Smads at linker regions. CDK2 and CDK4
phosphorylate Smad3 at Thr8 in the MH1 domain and
Thr178, Ser212 at sites in the linker region and this, in
turn, inhibits its transcriptional activity. Our study showed
that RBPMS can facilitate R-Smads phosphorylation on the
C-terminal SSXS motif and thus stimulate Smad-mediated
transcription. However, the protein complex involved in
this process remains to be determined. Since RBPMS
immunoprecipitate speciﬁcally phosphorylates Smad2 and
Smad3 on the C-terminal SSXS motif but not the linker
region (Figure 7 and data not shown) and RBPMS enhances
the transcriptional activity of Smad proteins, it is unlikely that
the previously reported kinases, such as ERK, JNK, p38 and
CDK2/4, are responsible for RBPMS-stimulated phosphory-
lation. Although RBPMS increases Smad transcriptional
activity in 293T cells even in the absence of TGF-b, the treat-
ment of a TGF-b neutralizing antibody completely abolishes
the RBPMS coactivation function, suggesting that 293T cells
express endogenous TGF-b sufﬁcient and required for
RBPMS activation. The inhibitor of the TGF-b receptor I,
TbR-I, completely abrogates the in vitro phosphorylation
activity of the RBPMS immunoprecipitate, further indicating
that TbR-I, which is activated by TGF-b, is required for the
RBPMS activity. Since RBPMS can interact both with TbR-I
and with Smad proteins in vivo, and TbR-I has been shown to
transiently associate with and phosphorylate Smad2 and
Smad3, it should be TbR-I in the RBPMS immunoprecipitate
that phosphorylates Smad2 and Smad3. The fact that RBPMS
does not associate with Smad2 and Smad3 phosphorylated on
their C-terminal SSXS motif further suggests that TbR-I,
RBPMS and unphosphorylated Smad2/3 may form a complex
and phosphorylation of Smad2 and Smad3 by the TbRI com-
plex results in dissociation of Smad2 and Smad3 from the
complex. RBPMS may act as an important factor for the
TbR-I-induced phosphorylation of Smad2 and Smad3
because RBPMS increases such phosphorylation in vivo.
Phosphorylation of Smad2 and Smad3 has been shown to
be required for their accumulation in the nucleus where the
proteins can function as transcriptional activators. Consistent
with this, RBPMS promotes the nuclear accumulation of
Smad2 and Smad3, and potentiates Smad-mediated transcrip-
tional activity. Thus, RBPMS increases TGF-b signaling pos-
sibly by increasing Smad2 and Smad3 phosphorylation at
the C-terminus, and promoting the nuclear accumulation of
the Smad complex. It will be interesting to determine the
precise mechanism by which RBPMS stimulates TGF-b/
Smad-mediated transactivation.
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